Golidocitinib

DB18057InvestigationalSmall molecule

Golidocitinib: Overview.

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK1
Curator reviewed
Formula / weight: C₂₅H₃₁N₉O₂ · 489.584 g/mol (avg)
Also known as: (.alpha.r)-n-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.,4-dimethyl-1-piperazineacetamide · 1-piperazineacetamide, n-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.,4-dimethyl-, (.alpha.r)-
Code names: AZD-4205

Resolves to

Compound

Structure

InChIKeyCVCVOSPZEVINRM-MRXNPFEDSA-NSMILESCOC1=NN(C)C=C1NC1=NC=CC(=N1)C1=CNC2=C(NC(=O)[C@@H](C)N3CCN(C)CC3)C=CC=C12

Targets

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

40Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Golidocitinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.